Association that Neuroimaging and Clinical Measures Have with Change in Arm Impairment in a Phase 3 Stroke Recovery Trial
Annals of Neurology · 2025
DOI: 10.1002/ana.27156 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Annals of Neurology, 2025. Verfasst von Anne Schwarz und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA. Hauptthemen laut MEDLINE: Stroke, Stroke Rehabilitation, Neuroimaging, Vagus Nerve Stimulation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: CSR NIH HHS, Center for Scientific Review.
Themen: Schlaganfall
Abstract (Originalsprache)
Objective
Vagus nerve stimulation (VNS) paired with rehabilitation therapy improved motor status compared to rehabilitation alone in the phase III VNS‐REHAB stroke trial, but treatment response was variable and not associated with any clinical measures acquired at baseline, such as age or side of paresis. We hypothesized that neuroimaging measures would be associated with treatment‐related gains, examining performance of regional injury measures versus global brain health measures in parallel with clinical measures.
Methods
Baseline magnetic resonance imaging (MRI) scans in the VNS‐REHAB trial were used to derive regional injury measures (extent of injury to corticospinal tract, the primary regional measure; plus extent of injury to precentral gyrus and postcentral gyrus; lesion volume; and lesion topography) and global brain health measures (degree of white matter hyperintensities, the primary global brain measure; plus volumes of cerebrospinal fluid, cortical gray matter, white matter, each thalamus, and total brain). Eight clinical measures assessed at baseline were also evaluated (treatment group, age, race, gender, paretic side, pre‐stroke dominant hand, time since stroke, and baseline Fugl‐Meyer upper extremity score). Bivariate analyses compared each measure with the primary trial end point (change in Fugl‐Meyer upper extremity score from baseline to end of 6 weeks of treatment) across all subjects, with secondary analyses examining trial groups separately.
Results
MRIs were available from 80 patients (age = 59.8 ± 9.5 years, 29 women). Across all patients, less white matter hyperintensities ( r = −0.25, p = 0.028) at baseline was associated with larger Fugl‐Meyer score change. In the VNS group, less white matter hyperintensities ( r = −0.37, p = 0.018) and larger ipsilesional thalamus volume ( r = 0.33, p = 0.046) were each associated with larger Fugl‐Meyer score change. Analysis of covariance (ANCOVA) analyses tested the interaction that each baseline measure had with treatment group and found that the model examining white matter hyperintensities had a significant interaction term, indicating 2.3 less change in Fugl‐Meyer Upper Extremity (FM‐UE) points in the VNS group relative to the control group for each point increase in modified Fazekas scale.
Interpretation
Neuroimaging measures are associated with extent of gains on the primary endpoint of a phase III stroke recovery trial. Among the neuroimaging measures examined, a measure of global brain health (extent of white matter hyperintensities) was better at explaining the change in arm impairment as compared with measures of regional injury; this was true when examining all study subjects as well as only those in the VNS group and is consistent with the global mechanism of action that VNS has throughout the cerebrum. Future studies can evaluate additional measures that further predict response to VNS therapy. The current findings suggest that individual patient neuroimaging results may be useful for a personalized medicine approach to stroke recovery therapeutics. ANN NEUROL 2025;97:709–719
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
- Department of Neurology, California Rehabilitation Institute, Los Angeles, CA.
- Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
- USC Neurorestoration Center and Department of Neurological Surgery, USC Keck School of Medicine, Los Angeles, CA.
- Department of Neurological Surgery, Rancho Los Amigos National Rehabilitation Center, Downey, CA.
- Department of Physical Medicine and Rehabilitation, The University of Texas Health Science Center McGovern Medical School, Houston, TX.
ORCID-Profile: Wuwei Feng, Steven C Cramer
Förderung
- CSR NIH HHS
- Center for Scientific Review
Zitieren
APA
Schwarz, A., Feldman, M., Le, V., Dawson, J., Liu, C. Y., Francisco, G. E., Wolf, S. L., Dixit, A., Alexander, J., Ali, R., Brown, B. L., Feng, W., DeMark, L., Hochberg, L. R., Kautz, S. A., Majid, A., O'Dell, M. W., Redgrave, J., Turner, D. L., …, & Cramer, S. C. (2025). Association that Neuroimaging and Clinical Measures Have with Change in Arm Impairment in a Phase 3 Stroke Recovery Trial. Annals of Neurology. https://doi.org/10.1002/ana.27156
Vancouver
Schwarz A, Feldman M, Le V, Dawson J, Liu CY, Francisco GE, et al. Association that Neuroimaging and Clinical Measures Have with Change in Arm Impairment in a Phase 3 Stroke Recovery Trial. Annals of Neurology. 2025. doi:10.1002/ana.27156
BibTeX
@article{Schwarz2025,
author = {Schwarz, Anne and Feldman, Marc and Le, Vu and Dawson, Jesse and Liu, Charles Y and Francisco, Gerard E and Wolf, Steven L and Dixit, Anand and Alexander, Jen and Ali, Rushna and Brown, Benjamin L and Feng, Wuwei and DeMark, Louis and Hochberg, Leigh R and Kautz, Steven A and Majid, Arshad and O'Dell, Michael W and Redgrave, Jessica and Turner, Duncan L and Kimberley, Teresa J and Cramer, Steven C},
title = {Association that Neuroimaging and Clinical Measures Have with Change in Arm Impairment in a Phase 3 Stroke Recovery Trial},
journal = {Annals of Neurology},
year = {2025},
doi = {10.1002/ana.27156}
}
EUVIMED